In May well, GENFIT disclosed interim data from your Stage III study as well as the outlook for elafibranor wasn't good. In the course of the interim analysis, GENFIT reported elafibranor failed to hit the predefined Key endpoint of NASH resolution with out a worsening of fibrosis. Elafibranor unsuccessful to https://troyklewl.blogoscience.com/17009726/the-smart-trick-of-zanubrutinib-that-no-one-is-discussing